IL6 and COVID-19: Nevertheless, a case report found no beneficial therapeutic effect of tocilizumab on one severe COVID-19 patient with low pretreatment plasma IL-6 (74.3 pg/mL), who developed viral myocarditis and lymphopenia after receiving tocilizumab treatment (65).